TP53 and non-small cell lung carcinoma: This order of efficacy (H1975 > A549 > H838) highlights a potential specificity of the extract toward the H1975 cell line, which harbors critical mutations in the EGFR and TP53 genes [62], including an EGFR exon 21 L858R mutation known to confer increased sensitivity to EGFR inhibitors—a staple in NSCLC treatment.